Funding Facility, page-22

Rikki,

I take great offence at the relentless destabilisation campaign against Noxopharm. The chief protagonist implies that Noxopharm scientists and their collaborators are idiots, but I know these people and they are brilliant.

Graham Kelly wants shareholders to benefit from the success of Noxopharm. He pursues this mission with incredible energy, when he could simply retire and enjoy his escape from terminal cancer. His greatest challenge is to avoid blowing a fuse when a former electrician tries to short-circuit his plans.

I wish the sniping would stop.​